

## SEQUENCE LISTING

<110> AVENTIS PHARMA S.A.

<120> HYBRID PROMOTERS

<130> PPAR INFLAMMATION

<140>

<141>

<160> 7

<170> PatentIn Ver. 2.1

<210> 1

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: PPRE element

<400> 1

caaaactagg tcaaaggtca

20

<210> 2

<211> 38

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: PPRE element

<400> 2

caaaactagg tcaaagggtca aaactagggtc aaagggtca

38

<210> 3

<211> 41

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: PPRE element

<400> 3

caaaactagg tcaaagggtca tcaaaactag gtcaaagggtc a

41

<210> 4

<211> 52

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: PPRE element

<400> 4

caaaactagg tcaaagggtca tgtcttagg cccaaaacta ggtcaaagggt ca

52

<210> 5

<211> 271

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: fragment of the PLA2s promoter

<400> 5

```
cgcggcacaaa ctgcctgaaa tgtgttttgg catcagctac tgacacgtaa gggttcccaa 60
tcctcaactc tgtcctgcca gctgatgagg ggaaggaaag ggattaccta ggggtatggg 120
cgaccaatcc tgagtcacc aactgaccac gcccatcccc agccttgtgc ctcacctacc 180
cccaacctcc cagagggagc agctatttaa ggggagcagg agtgcagAAC aaacaagacg 240
gcctggggat acaactctgg agtcctctga g 271
```

<210> 6

<211> 332

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description/PPRE/PLA2s hybrid promoter

<400> 6

```
gtaccaattc gacaaaacta ggtcaaagg catcaaaact aggtcaaagg tcaaattcga 60
acgcggcaaaa actgcctgaa atgtgttttg gcatcagcta ctgacacgta aggtttccca 120
atcctcaact ctgtcctgcc agctgatgag gggaaggaaa gggattacct aggggtatgg 180
gcgaccaatc ctgagtcacc caactgacca cgcccatccc cagccttgtg cctcacctac 240
cccaacctcc ccagagggag cagctattta aggggagcag gagtgcagaa caacaagac 300
ggcctgggga tacaactctg gagtcctctg ag 332
```

<210> 7

<211> 944

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence description: sequence conferring specificity of expression

<400> 7

tgccggcctc gcggtgagcc ctgateccgc tcggggctcc ccagtcgctg gtgctgctga 60  
cgctgctcat cgccgcgggc ctacgggtgc agggccagga tgcccgtaag tcgcccgcgc 120  
ccccctgccta ctcccttgac ttgtgacctt ttctctccta ctccctcccc caagtactag 180  
gatcccccta gagcttgagc atctgggatt ggcagcgatg gcttcagat gggctgaaac 240  
cctgcccgtg tttattttaa ctgggttcctc gtggagagct gtgaatcggg ctctgtatgc 300  
gcttgagaaa agccccattc atgagaggca agggccagtg ggtcccccaa ctccccgacc 360  
ccccctctccc acaatgcaca gcctccccgc cctcatcccc cccccacccc ccgtgcccgc 420  
ctgccgccac cttcagatcg atctgggatt ggcagcgatg gcttcagat gggctgaaac 480  
cctgcccgtg tttattttaa ctgggttcctc gtggagagct gtgaatcggg ctctgtatgc 540  
gcttgagaaa agccccattc atgagaggca agggccagtg ggtcccccaa ctccccgacc 600  
ccccctctccc acaatgcaca gcctccccgc cctcatcccc cccccacccc ccgtgcccgc 660  
cctgcccgtg cctccagatc tccagctaga ggatctgcga ctctagggtt cgaaatcgat 720  
aagccaagct ctagtggatc ccccggtg cagatctgta gggcgcagta gtccagggtt 780  
tccttgatga tgtcatactt atcctgtccc tttttttccc acagctcgcg gttgaggaca 840  
aactcttcgc ggtctttcca gtggggatcg acggtatcga taagcttgat gatctgtgac 900  
atggcggatc ccgtcgtttt acaacgtcgt gactgggaaa accc 944